- Gilead Sciences (NASDAQ:GILD) is trading ~2.1% lower in the post-market despite beating expectations with its revenue and adjusted EPS in Q2 2021 financials.
- Total revenue has risen 21% YoY compared to the 11% YoY contraction seen in the previous
Gilead Sciences tightens 2021 guidance; remdesivir sales slide
Recommended For You
About GILD Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| GILD | - | - |
| Gilead Sciences, Inc. | ||